Novartis initiates strategic review of listed Indian entity including taking a call on its 70.68% shareholding. Industry pundits point to potential suitors and options that may be at play.
Way back in March 1996, Swiss pharmaceutical companies Ciba-Geigy and Sandoz. decided to merge and form what was then the world’s biggest life sciences combine christened Novartis.
Novartis AG initiates strategic review of listed entity in India
The India merger of local arms Hindustan Ciba-Geigy Limited and Sandoz (India) Limited came a year on, post various approvals...
The Belgian drugmaker is boosting its biologics capacity over the pond.
After in-licensing a cardiovascular candidate last year, AstraZeneca has signed a strategic drug discovery alliance, which could generate billions of dollars in payments to the Chinese firm.
Public Company Edition: Insmed raised $750m after reporting positive Phase IIb data in PAH, Cogent accessed up to $400m in new debt, Kelun-Biotech netted $250m in a placement of shares and ADC revealed a $100m private placement. In strategic updates, Recursion cut 20% of its jobs.
Deal Snapshot: Including its internal efforts with bimagrumab, Lilly has been seeking a muscle-sparing therapy to complement GLP-1 obesity drugs, such as Zepbound.
Study to add to safety and tolerability data for infused formulation and may help identify optimal dose for future pivotal trial.
Public Company Edition: Insmed raised $750m after reporting positive Phase IIb data in PAH, Cogent accessed up to $400m in new debt, Kelun-Biotech netted $250m in a placement of shares and ADC revealed a $100m private placement. In strategic updates, Recursion cut 20% of its jobs.
Deal Snapshot: Including its internal efforts with bimagrumab, Lilly has been seeking a muscle-sparing therapy to complement GLP-1 obesity drugs, such as Zepbound.
